Anthocyanins as antidiabetic agents—in vitro and in silico approaches of preventive and therapeutic effects

63Citations
Citations of this article
187Readers
Mendeley users who have this article in their library.

Abstract

Many efforts have been made in the past two decades into the search for novel natural and less-toxic anti-diabetic agents. Some clinical trials have assigned this ability to anthocyanins, although different factors like the food source, the amount ingested, the matrix effect and the time of consumption (before or after a meal) seem to result in contradictory conclusions. The possible mechanisms involved in these preventive or therapeutic effects will be discussed—giving emphasis to the latest in vitro and in silico approaches. Therapeutic strategies to counteract metabolic alterations related to hyperglycemia and Type 2 Diabetes Mellitus (T2DM) may include: (a) Inhibition of carbohydrate-metabolizing enzymes; (b) reduction of glucose transporters expression or activity; (c) inhibition of glycogenolysis and (d) modulation of gut microbiota by anthocyanin breakdown products. These strategies may be achieved through administration of individual anthocyanins or by functional foods containing complexes of anthocyanin:carbohydrate:protein.

Cite

CITATION STYLE

APA

Oliveira, H., Fernandes, A., Brás, N. F., Mateus, N., de Freitas, V., & Fernandes, I. (2020, September 1). Anthocyanins as antidiabetic agents—in vitro and in silico approaches of preventive and therapeutic effects. Molecules. MDPI AG. https://doi.org/10.3390/molecules25173813

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free